KABANAT 60 MG

The defining feature of Cabazitaxel is its taxane microtubule inhibitor activity. Binds tubulin and stabilizes microtubules, disrupting mitosis. Its antitumor activity depends on disrupting microtubule function, a mechanism shared by the class but applied in different disease-specific regimens. Within this database it is listed under Chemotherapy; Taxane. The principal indications are Metastatic castration-resistant prostate cancer previously treated with docetaxel in the labeled setting, with Prostate Cancer identified as the associated tumor types. Its treatment role can differ substantially between these settings, so the disease context matters as much as the drug class. Regimens listed for the medicine include Cabazitaxel + prednisone/prednisolone; post-docetaxel mCRPC regimens. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. Where a molecular alteration, receptor status, or prior-treatment requirement appears in the indication, that criterion is part of the clinical context rather than an optional detail. The medicine may consequently occupy an induction, maintenance, adjuvant, metastatic, salvage, or supportive position depending on the setting recorded here. The summary is descriptive and does not provide individualized dosing or administration instructions. Current product information and disease-specific guidance should be checked before clinical application.